Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria
Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Subcutaneous pegcetacoplan (EMPAVELI
®
in the USA and ASPAVELI
®
in the EU) is the first complement component 3 (C3) inhibitor approved for the treatment of adults with paroxysmal nocturnal haemoglobinuria (PNH) in the USA, and in adults with PNH who are anaemic after ≥ 3 months of treatment with a C5 inhibitor in the EU. In the phase I...
Alternative Titles
Full title
Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10234880
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10234880
Other Identifiers
ISSN
0012-6667
E-ISSN
1179-1950
DOI
10.1007/s40265-022-01809-w
